MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test

Envisia testing is covered as a tissue‑based genomic classifier for patients with interstitial lung disease suspected of idiopathic pulmonary fibrosis when HRCT does not show a definitive UIP pattern and no other cause of ILD is identified; testing must use bronchoscopy transbronchial biopsy (TBB) tissue. The test is intended to provide a categorical UIP versus non‑UIP result to aid diagnosis and possibly avoid surgical lung biopsy; it is not covered when HRCT is definitive for UIP, when a known cause of ILD exists, or for uses outside the intended diagnostic purpose.

"Envisia is covered for patients with interstitial lung disease (ILD) who are suspected of having idiopathic pulmonary fibrosis (IPF) when high-resolution CT (HRCT) does not show a definitive usual ..."

Sign up to see full coverage criteria, indications, and limitations.